RxDoctor Payments Data

Charles Harring, MD

Cardiovascular Disease · Delray Beach, FLNPI 1295735660

Payments from drug & device makers

$17,405in general payments, 2019–2025

Across 821 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$2K
  • Abbott$2K
  • AstraZeneca$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Amarin Pharma, Inc.$746
  • plus $9K from 49 others

What the payments were for

  • Food & beverage$17,14498%
  • Education$2612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,405 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,831,823
Medicare patients
2,244
Services billed
15,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis20$446,423
EliquisApixaban444$422,670
XareltoRivaroxaban186$201,605
EntrestoSacubitril/Valsartan151$160,549
Repatha SureclickEvolocumab113$109,522
FarxigaDapagliflozin Propanediol44$51,690
BrilintaTicagrelor43$31,202
JardianceEmpagliflozin19$22,468
Repatha SyringeEvolocumab11$15,853
MultaqDronedarone Hcl12$12,157
OzempicSemaglutide12$11,411
Nebivolol Hcl136$7,710
Enoxaparin Sodium16$6,353
EdarbiAzilsartan Medoxomil15$6,189
Rosuvastatin Calcium429$5,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$623$869,092464 claims
Johnson & JohnsonXarelto$1,033$201,605186 claims
NovartisEntresto$664$160,549151 claims
AstraZenecaFarxiga, Brilinta$1,173$82,89387 claims
Boehringer IngelheimJardiance$471$22,46819 claims
Sanofi-aventis U.S. LLCMultaq$174$12,15712 claims
Novo NordiskOzempic$60$11,41112 claims
Arbor Pharmaceuticals, Inc.Edarbi$59$6,18915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →